FDA.reportPublic FDA data

lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Cimduo]

RxCUI
2003255
RxNorm name
lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Cimduo]
Display name
lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Cimduo]
Full name
lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Cimduo]
Term type
SBD
Status
DailyMed mapping
Updated
2026-06-04 23:39:11

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
CIMDUOLAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATEViatris Specialty LLCa300f04d-118f-4136-aaf3-ddfd00197f862021-02-15Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2003255

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
a300f04d-118f-4136-aaf3-ddfd00197f86Cimduo 300 MG / 300 MG Oral Tablet [PSN] · lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Cimduo] [SBD] · 3TC 300 MG / Tenofovir disoproxil fumarate 300 MG Oral Tablet [Cimduo] [SY] · Cimduo (lamivudine 300 MG / tenofovir disoproxil fumarate 300 MG (equivalent to tenofovir disoproxil 245 MG)) Oral Tablet [SY]45These highlights do not include all the information needed to use CIMDUO safely and effectively. See full prescribing information for CIMDUO . CIMDUO ® (lamivudine and tenofovir disoproxil fumarate) tablets, for oral use Initial U.S. Approval: 201820210215